447 related articles for article (PubMed ID: 23393200)
41. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
42. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
43. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
[TBL] [Abstract][Full Text] [Related]
44. Clinical Application of Chromosome Microarray Analysis in the Diagnosis of Lipomatous Tumors.
Pei J; Flieder DB; Talarchek JN; Cooper HS; Patchefsky AS; Wei S
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):592-598. PubMed ID: 33734108
[TBL] [Abstract][Full Text] [Related]
45. TGF-β Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma.
Santhana Kumar K; Neve A; Guerreiro Stucklin AS; Kuzan-Fischer CM; Rushing EJ; Taylor MD; Tripolitsioti D; Behrmann L; Kirschenbaum D; Grotzer MA; Baumgartner M
Cell Rep; 2018 Jun; 23(13):3798-3812.e8. PubMed ID: 29949765
[TBL] [Abstract][Full Text] [Related]
46. Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth.
Santhana Kumar K; Brunner C; Schuster M; Kopp LL; Gries A; Yan S; Jurt S; Moehle K; Bruns D; Grotzer M; Zerbe O; Schneider G; Baumgartner M
Cell Oncol (Dordr); 2023 Apr; 46(2):331-356. PubMed ID: 36495366
[TBL] [Abstract][Full Text] [Related]
47. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation.
Klint P; Kanda S; Kloog Y; Claesson-Welsh L
Oncogene; 1999 Jun; 18(22):3354-64. PubMed ID: 10362356
[TBL] [Abstract][Full Text] [Related]
48. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.
Louis-Brennetot C; Coindre JM; Ferreira C; Pérot G; Terrier P; Aurias A
Genes Chromosomes Cancer; 2011 Nov; 50(11):896-907. PubMed ID: 21910158
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas.
Hostein I; Pelmus M; Aurias A; Pedeutour F; Mathoulin-Pélissier S; Coindre JM
J Pathol; 2004 Jan; 202(1):95-102. PubMed ID: 14694526
[TBL] [Abstract][Full Text] [Related]
50. Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma.
Hélias-Rodzewicz Z; Pédeutour F; Coindre JM; Terrier P; Aurias A
Genes Chromosomes Cancer; 2009 Nov; 48(11):943-52. PubMed ID: 19626636
[TBL] [Abstract][Full Text] [Related]
51. Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2.
Zhang Y; Lin Y; Bowles C; Wang F
J Biol Chem; 2004 Dec; 279(53):55348-54. PubMed ID: 15513912
[TBL] [Abstract][Full Text] [Related]
52. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
[TBL] [Abstract][Full Text] [Related]
54. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
[TBL] [Abstract][Full Text] [Related]
55. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
56. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
57. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
[TBL] [Abstract][Full Text] [Related]
58. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
[TBL] [Abstract][Full Text] [Related]
59. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
[TBL] [Abstract][Full Text] [Related]
60. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
